Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

<p><strong>Objectives</strong></p><p>Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity. Different clinical indexes have been proposed to define these disease states including the mi...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Coates, L, Rahman, P, Psaradellis, E, Rampakakis, E, Osborne, B, Lehman, A, Nantel, F
Formaat:	Journal article
Gepubliceerd in:	Oxford University Press 2018

Gelijkaardige items

Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
door: Emmanouil Rampakakis, et al.
Gepubliceerd in: (2020-08-01)

Golimumab for the treatment of psoriatic arthritis
door: H Yang, et al.
Gepubliceerd in: (2011-05-01)

Golimumab in the treatment of psoriatic arthritis: efficacy and safety
door: Tatiana Viktorovna Korotaeva, et al.
Gepubliceerd in: (2015-09-01)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
door: Proton Rahman, et al.
Gepubliceerd in: (2020-09-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
door: M. Rossini, et al.
Gepubliceerd in: (2015-03-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
door: Lubrano, E, et al.
Gepubliceerd in: (2019)

Considerations for the definition of remission criteria in psoriatic arthritis
door: Mease, P, et al.
Gepubliceerd in: (2017)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
door: Sydney Moore McIntosh, et al.
Gepubliceerd in: (2023-07-01)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
door: Melissa A Michelon, et al.
Gepubliceerd in: (2010-05-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
door: Ennio Lubrano, et al.
Gepubliceerd in: (2019-08-01)

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
door: Proton Rahman, et al.
Gepubliceerd in: (2020-11-01)

Remission in psoriatic arthritis—where are we now?
door: Coates, L, et al.
Gepubliceerd in: (2017)

What should be the primary target of "treat to target" in psoriatic arthritis?
door: Coates, LC, et al.
Gepubliceerd in: (2018)

Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort
door: van Mens, L, et al.
Gepubliceerd in: (2017)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
door: Coates, LC, et al.
Gepubliceerd in: (2018)

Novel concepts in psoriatic arthritis management: Can we treat to target?
door: Tucker, L, et al.
Gepubliceerd in: (2018)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
door: Coates, L, et al.
Gepubliceerd in: (2022)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
door: M. Elaine Husni, et al.
Gepubliceerd in: (2022-03-01)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
door: Coates, L, et al.
Gepubliceerd in: (2018)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
door: Dures, E, et al.
Gepubliceerd in: (2020)

THE EFFECT OF GOLIMUMAB ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
door: L. A. Knyazeva, et al.
Gepubliceerd in: (2018-03-01)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
door: Philip Mease, et al.
Gepubliceerd in: (2020-11-01)

Using etanercept to maintain remission of psoriatic arthritis during pregnancy
door: Ibrahim A Al-Homood, et al.
Gepubliceerd in: (2014-01-01)

2-years outcomes of the treat-to-target strategy in early psoriatic arthritis
door: E. Yu. Loginova, et al.
Gepubliceerd in: (2022-11-01)

GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
door: Wordsworth, P, et al.
Gepubliceerd in: (2009)

Difficult-to-treat psoriatic arthritis. Data from the All-Russian registry of patients with psoriatic arthritis
door: E. Yu. Loginova, et al.
Gepubliceerd in: (2024-10-01)

Use of a multidimensional RAPID3 questionnaire to assess the achievement of remission and minimal disease activity in patients with early psoriatic arthritis treated according to Treat-to-target strategy
door: E. Yu. Loginova, et al.
Gepubliceerd in: (2019-01-01)

Psoriatic arthritis: prospects for the future
door: Hackett, S, et al.
Gepubliceerd in: (2022)

Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
door: Taylor, P, et al.
Gepubliceerd in: (2011)

Measuring outcomes in psoriatic arthritis
door: Ogdie, A, et al.
Gepubliceerd in: (2020)

Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study
door: Leung, Y-Y, et al.
Gepubliceerd in: (2023)

Psoriatic arthritis
door: FitzGerald, O, et al.
Gepubliceerd in: (2021)

Psoriatic arthritis: prospects for the future
door: Simon Hackett, et al.
Gepubliceerd in: (2022-03-01)

Golimumab therapy-induced indicators of X-ray inflammation progression and magnitude according to magnetic resonance imaging evidence in patients with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis
door: Aleksandr Viktorovich Smirnov
Gepubliceerd in: (2013-06-01)

The road to personalised medicine in psoriatic arthritis
door: White, JPE, et al.
Gepubliceerd in: (2021)

Psoriatic arthritis: An up to date overview
door: Simon Hackett, et al.
Gepubliceerd in: (2020-01-01)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
door: Ye, W, et al.
Gepubliceerd in: (2018)

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries
door: Gorlier, C, et al.
Gepubliceerd in: (2018)

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
door: Sofia Lanz, et al.
Gepubliceerd in: (2021-08-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
door: Ananaya Datta-Mitra, et al.
Gepubliceerd in: (2014-01-01)